Cargando…
Assessment of the feasibility of exon 45–55 multiexon skipping for duchenne muscular dystrophy
BACKGROUND: The specific skipping of an exon, induced by antisense oligonucleotides (AON) during splicing, has shown to be a promising therapeutic approach for Duchenne muscular dystrophy (DMD) patients. As different mutations require skipping of different exons, this approach is mutation dependent....
Autores principales: | van Vliet, Laura, de Winter, Christa L, van Deutekom, Judith CT, van Ommen, Gert-Jan B, Aartsma-Rus, Annemieke |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2611974/ https://www.ncbi.nlm.nih.gov/pubmed/19046429 http://dx.doi.org/10.1186/1471-2350-9-105 |
Ejemplares similares
-
Antisense-induced exon skipping for duplications in Duchenne muscular dystrophy
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2007) -
Exon skipping for DMD
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2012) -
Dual exon skipping in myostatin and dystrophin for Duchenne muscular dystrophy
por: Kemaladewi, Dwi U, et al.
Publicado: (2011) -
Development of Multiexon Skipping Antisense Oligonucleotide Therapy for Duchenne Muscular Dystrophy
por: Aoki, Yoshitsugu, et al.
Publicado: (2013) -
The Effect of 6-Thioguanine on Alternative Splicing and Antisense-Mediated Exon Skipping Treatment for Duchenne Muscular Dystrophy
por: Verhaart, Ingrid E. C., et al.
Publicado: (2012)